Effect of Candesarutan and Piogritazon in hypertensive patients with diabetes

Effect of Candesarutan and Piogritazon in hypertensive patients with diabetes - Effect of Candesarutan and Piogritazon in hypertensive patients with diabetes

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000007921

Enrollment

100

Registered

2012-05-09

Start date

2008-05-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension and Hypertensive diabetic

Interventions

24-week treatment of high dose Candesarutan in hypertension. 24-week treatment of Candesarutan and Piogritazon in hypertensive diabetic.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with type 2 diabetes and hypertension(Age 20-75 years). Patients who has not been taking Piogritazon. Informed consent obtained.

Exclusion criteria

Exclusion criteria: Contraindicated of Piogritazon and Candesartan. Informed consent can not be obtained. Patients judged to be unsuitable.

Design outcomes

Primary

Measure	Time frame
Systolic Blood Pressure, Diastolic Blood Pressure, HbA1c and surrogate marker of arterial sclerosis	—

Countries

Japan

Contacts

Public ContactMasaya Sakamoto

The jikei University School of Medicin Division of Diabetes, Metabolism and Endocrinology, Department of Internal Medicine

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026